{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T19:38:17Z","timestamp":1785181097655,"version":"3.55.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003100","name":"French Federation of Cardiology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003100","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-23-IAHU-0011"],"award-info":[{"award-number":["ANR-23-IAHU-0011"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-05-PNRA-018"],"award-info":[{"award-number":["ANR-05-PNRA-018"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis Plus"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.athplu.2025.04.003","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T21:05:43Z","timestamp":1746738343000},"page":"35-42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Plasma apolipoprotein concentrations and occurrence of cardiovascular events in the general population: an exploratory analysis"],"prefix":"10.1016","volume":"60","author":[{"given":"Avedis","family":"Torossian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelise","family":"Genoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zichun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Jolivet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika\u00ebl","family":"Croyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ars\u00eanio Rodrigues","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Dejean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Viguerie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cendrine","family":"Cabou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Perret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Ferri\u00e8res","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanina","family":"Bongard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0985-3152","authenticated-orcid":false,"given":"Laurent O.","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.athplu.2025.04.003_bib1","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.acvd.2016.01.011","article-title":"Prevalence and economic burden of cardiovascular diseases in France in 2013 according to the national health insurance scheme database","volume":"109","author":"Tuppin","year":"2016","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.athplu.2025.04.003_bib2","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/j.jacc.2022.11.005","article-title":"The global burden of cardiovascular diseases and risk: a compass for future health","volume":"80","author":"Vaduganathan","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.athplu.2025.04.003_bib3","unstructured":"Global Health Estimates. https:\/\/www.who.int\/data\/global-health-estimates, 2022 (accessed 19 February 2025)."},{"key":"10.1016\/j.athplu.2025.04.003_bib4","unstructured":"WHO reveals leading causes of death and disability worldwide: 2000-2019. https:\/\/www.who.int\/news\/item\/09-12-2020-who-reveals-leading-causes-of-death-and-disability-worldwide-2000-2019, 2020 (accessed 19 February 2025)."},{"key":"10.1016\/j.athplu.2025.04.003_bib5","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study","volume":"76","author":"Roth","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.athplu.2025.04.003_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003853","article-title":"Long-term risk of a major cardiovascular event by apoB, apoA-1, and the apoB\/apoA-1 ratio-Experience from the Swedish AMORIS cohort: a cohort study","volume":"18","author":"Walldius","year":"2021","journal-title":"PLoS Med"},{"key":"10.1016\/j.athplu.2025.04.003_bib7","unstructured":"Apolipoprotein E for risk assessment and management of cardiovascular disease. https:\/\/beonbrand.getbynder.com\/m\/332d08c4faae155a\/original\/Apolipoprotein-E-for-Risk-Assessment-and-Management-of-Cardiovascular-Disease.pdf, 2025 (accessed 1 March 2025)."},{"key":"10.1016\/j.athplu.2025.04.003_bib8","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1093\/cvr\/cvad177","article-title":"Exploring apolipoprotein C-III: pathophysiological and pharmacological relevance","volume":"119","author":"Packard","year":"2024","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.athplu.2025.04.003_bib9","doi-asserted-by":"crossref","DOI":"10.1503\/cmaj.230048","article-title":"Apolipoprotein B in cardiovascular risk assessment","volume":"195","author":"Ahmad","year":"2023","journal-title":"CMAJ Canadian Medical Association Journal"},{"key":"10.1016\/j.athplu.2025.04.003_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/metabo11100690","article-title":"Apolipoprotein B and cardiovascular disease: biomarker and potential therapeutic target","volume":"11","author":"Behbodikhah","year":"2021","journal-title":"Metabolites"},{"key":"10.1016\/j.athplu.2025.04.003_bib11","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1001\/jamacardio.2019.3780","article-title":"Apolipoprotein B particles and cardiovascular disease: a narrative review","volume":"4","author":"Sniderman","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.athplu.2025.04.003_bib12","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.jacc.2021.01.027","article-title":"Apolipoprotein B and non-HDL cholesterol better reflect residual risk than LDL cholesterol in statin-treated patients","volume":"77","author":"Johannesen","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.athplu.2025.04.003_bib13","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1161\/01.ATV.8.6.737","article-title":"High density lipoprotein cholesterol and mortality. The Framingham Heart Study","volume":"8","author":"Wilson","year":"1988","journal-title":"Arteriosclerosis"},{"issue":"2","key":"10.1016\/j.athplu.2025.04.003_bib14","first-page":"61","article-title":"Apolipoproteins and Cardiovascular diseases\u202f: An overview","volume":"28","author":"Singh","year":"1998","journal-title":"Indian Anthropologist"},{"key":"10.1016\/j.athplu.2025.04.003_bib15","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1177\/0004563219827620","article-title":"Apolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia","volume":"56","author":"Renee Ruhaak","year":"2019","journal-title":"Ann Clin Biochem"},{"key":"10.1016\/j.athplu.2025.04.003_bib16","doi-asserted-by":"crossref","DOI":"10.4414\/smw.2013.13781","article-title":"Pro- or anti-inflammatory role of apolipoprotein A-1 in high-density lipoproteins?","volume":"143","author":"Vuilleumier","year":"2013","journal-title":"Swiss Med Wkly"},{"key":"10.1016\/j.athplu.2025.04.003_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003062","article-title":"Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: a multivariable Mendelian randomisation analysis","volume":"17","author":"Richardson","year":"2020","journal-title":"PLoS Med"},{"key":"10.1016\/j.athplu.2025.04.003_bib18","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.acvd.2012.11.003","article-title":"Attainment of low-density lipoprotein cholesterol target in the French general population according to levels of cardiovascular risk: insights from the MONA LISA study","volume":"106","author":"Bongard","year":"2013","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.athplu.2025.04.003_bib19","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ancard.2012.03.003","article-title":"[Assessment and characteristics of chronic renal insufficiency in France]","volume":"61","author":"Bongard","year":"2012","journal-title":"Ann Cardiol Angeiol"},{"key":"10.1016\/j.athplu.2025.04.003_bib20","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/261878","article-title":"Validation of the Friedewald formula in patients with metabolic syndrome","volume":"2014","author":"Knopfholz","year":"2014","journal-title":"Cholesterol"},{"key":"10.1016\/j.athplu.2025.04.003_bib21","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1194\/jlr.D120000835","article-title":"A high-throughput mass spectrometry-based assay for large-scale profiling of circulating human apolipoproteins","volume":"61","author":"Blanchard","year":"2020","journal-title":"J Lipid Res"},{"key":"10.1016\/j.athplu.2025.04.003_bib22","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.2215\/CJN.06870909","article-title":"Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size","volume":"5","author":"Michels","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.athplu.2025.04.003_bib23","first-page":"581","article-title":"Partial least squares","volume":"vol. 6","author":"Wold","year":"1985"},{"key":"10.1016\/j.athplu.2025.04.003_bib24","doi-asserted-by":"crossref","first-page":"31068","DOI":"10.1074\/jbc.M703552200","article-title":"Structural insight into the dual ligand specificity and mode of high density lipoprotein association of apolipoprotein D","volume":"282","author":"Eichinger","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.athplu.2025.04.003_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.738991","article-title":"The lipocalin apolipoprotein D functional portrait: a systematic review","volume":"12","author":"Sanchez","year":"2021","journal-title":"Front Physiol"},{"key":"10.1016\/j.athplu.2025.04.003_bib26","doi-asserted-by":"crossref","first-page":"17023","DOI":"10.1073\/pnas.1315986110","article-title":"Identification of apolipoprotein D as a cardioprotective gene using a mouse model of lethal atherosclerotic coronary artery disease","volume":"110","author":"Tsukamoto","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.athplu.2025.04.003_bib27","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s12020-018-1621-5","article-title":"High ApoD protein level in the round ligament fat depot of severely obese women is associated with an improved inflammatory profile","volume":"61","author":"Desmarais","year":"2018","journal-title":"Endocrine"},{"key":"10.1016\/j.athplu.2025.04.003_bib28","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/j.metabol.2011.04.013","article-title":"Genetic deficiency of apolipoprotein D in the mouse is associated with nonfasting hypertriglyceridemia and hyperinsulinemia","volume":"60","author":"Jim\u00e9nez-Palomares","year":"2011","journal-title":"Metabolism"},{"key":"10.1016\/j.athplu.2025.04.003_bib29","doi-asserted-by":"crossref","first-page":"17","DOI":"10.18632\/aging.100004","article-title":"Apolipoprotein D in lipid metabolism and its functional implication in atherosclerosis and aging","volume":"1","author":"Perdomo","year":"2009","journal-title":"Aging"},{"key":"10.1016\/j.athplu.2025.04.003_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/antiox12051027","article-title":"In oxidative stress and inflammation","volume":"12","author":"Fyfe-Desmarais","year":"2023","journal-title":"Antioxidants"},{"key":"10.1016\/j.athplu.2025.04.003_bib31","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.atherosclerosis.2021.12.011","article-title":"Elevated levels of apolipoprotein D predict poor outcome in patients with suspected or established coronary artery disease","volume":"341","author":"Annema","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.athplu.2025.04.003_bib32","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.4103\/0366-6999.164983","article-title":"A new predictor and therapeutic target in cardiovascular disease?","volume":"128","author":"Yang","year":"2015","journal-title":"Chin Med J (Engl)"},{"issue":"1 4","key":"10.1016\/j.athplu.2025.04.003_bib33","first-page":"1","article-title":"Clusterin and LRP2 are critical components of the hypothalamic feeding regulatory pathway","volume":"4","author":"Gil","year":"2013","journal-title":"Nat Commun"},{"key":"10.1016\/j.athplu.2025.04.003_bib34","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/eurheartj\/ehab691","article-title":"Glycosylated apolipoprotein J in cardiac ischaemia: molecular processing and circulating levels in patients with acute ischaemic events","volume":"43","author":"Cubedo","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.athplu.2025.04.003_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2023.131291","article-title":"Changes in circulating ApoJ-Glyc levels in patients with suspected acute coronary syndrome: the EDICA trial","volume":"391","author":"Kaski","year":"2023","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.athplu.2025.04.003_bib36","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.atherosclerosis.2009.11.022","article-title":"Its relevance to cardiovascular disease","volume":"209","author":"Crook","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.athplu.2025.04.003_bib37","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1161\/ATVBAHA.120.314965","article-title":"Genome-wide association study highlights APOH as a novel locus for lipoprotein(a) levels-brief report","volume":"41","author":"Hoekstra","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.athplu.2025.04.003_bib38","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-022-01703-5","article-title":"Role of apolipoprotein C1 in lipoprotein metabolism, atherosclerosis and diabetes: a systematic review","volume":"21","author":"Rouland","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.athplu.2025.04.003_bib39","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1194\/jlr.M022988","article-title":"Constitutive inhibition of plasma CETP by apolipoprotein C1 is blunted in dyslipidemic patients with coronary artery disease","volume":"53","author":"Pillois","year":"2012","journal-title":"J Lipid Res"},{"key":"10.1016\/j.athplu.2025.04.003_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20235939","article-title":"Apolipoprotein C1: its pleiotropic effects in lipid metabolism and beyond","volume":"20","author":"Fuior","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.athplu.2025.04.003_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.901408","article-title":"Inhibition of vascular inflammation by apolipoprotein A-IV","volume":"9","author":"Shearston","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.athplu.2025.04.003_bib42","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.atherosclerosis.2018.11.006","article-title":"Plasma levels of apolipoproteins C-III, A-IV, and E are independently associated with stable atherosclerotic cardiovascular disease","volume":"281","author":"Dittrich","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.athplu.2025.04.003_bib43","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","article-title":"Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study","volume":"364","author":"Yusuf","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.athplu.2025.04.003_bib44","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/MOL.0000000000000142","article-title":"In lipid metabolism and cardiometabolic diseases","volume":"26","author":"Borup","year":"2015","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.athplu.2025.04.003_bib45","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1161\/CIRCULATIONAHA.119.045323","article-title":"Reduced apolipoprotein M and adverse outcomes across the spectrum of human heart failure","volume":"141","author":"Chirinos","year":"2020","journal-title":"Circulation"}],"container-title":["Atherosclerosis Plus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667089525000100?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667089525000100?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T11:02:54Z","timestamp":1778929374000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667089525000100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":45,"alternative-id":["S2667089525000100"],"URL":"https:\/\/doi.org\/10.1016\/j.athplu.2025.04.003","relation":{},"ISSN":["2667-0895"],"issn-type":[{"value":"2667-0895","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Plasma apolipoprotein concentrations and occurrence of cardiovascular events in the general population: an exploratory analysis","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis Plus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.athplu.2025.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}